



February 7, 2014

Intra-Cellular Therapies to Present at Two Upcoming Healthcare Conferences

Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) today announced Dr. Sharon Mates, Ph.D., President and Chief Executive Officer, will present at the 16th Annual BIO CEO and Investor Conference on February 10, 2014 at 4:30 p.m. Eastern Time at the Waldorf Astoria New York. Dr. Mates is also scheduled to present in a fireside chat discussion at the 2014 Leerink Global Healthcare Conference on February 12th, 2014 at 08:50 a.m. Eastern Time also at the Waldorf Astoria New York.

The live and archived webcast of the company presentations from both conferences can be accessed under "Events and Presentations" in the Intra-Cellular Therapies Investor Relations section of the Company website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software. The archived replay will be available on the Intra-Cellular Therapies website for one week following the conference.

About Intra-Cellular Therapies

Intra-Cellular Therapies (the "Company") is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disease and other disorders of the central nervous system ("CNS"). The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, behavioral disturbances in dementia, bipolar disorder and other neuropsychiatric and neurological disorders. In December 2013, the Company announced positive topline results from the Company's randomized, placebo- and active-controlled Phase II clinical trial of ITI-007 in patients with acutely exacerbated schizophrenia. In addition, the Company is also developing other drug candidates utilizing its phosphodiesterase platform and other proprietary chemistry platforms. The Company has a collaboration to develop certain PDE1 inhibitors with Takeda Pharmaceutical Company for the treatment of cognitive deficits in schizophrenia and other CNS disorders. In February 2013, the Company announced the successful completion of a Phase I single rising dose study of the lead molecule in the ITI/Takeda collaboration, ITI-214. The Company has additional programs in the areas of Parkinson's disease, Alzheimer's disease, depression and cardiovascular disease.

Contact:

Allen A. Fienberg, Ph.D.
Vice President
Business Development of Intra-Cellular Therapies, Inc.
212-923-3344

Burns McClellan, Inc.
Lisa Burns/Angeli Kolhatkar (Investors)
Justin Jackson (Media)
\n jjackson@burnsmc.com
Phone 212-213-0006